MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MP-17-0000764
Market Cap
₹12.68 Cr
BERLDRG · BSE
Share Price
₹25.94
+3.76% today
Revenue
₹19.31 Cr
FY 2025-26 · -8.7% YoY
EBITDA
₹2.43 Cr
Margin 12.6%
Net Profit
₹0.44 Cr
FY 2025-26 · -24.1% YoY
P/E (TTM)
18.9x
P/B 1.2x
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹5.07 Cr
Issued & subscribed
About Beryl Drugs Limited
Data last updated:
Beryl Drugs Limited is a public limited company based in Indore, Madhya Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 August 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN L02423MP1993PLC007840. Its GSTIN is 23AABCB2664H1Z0 (Madhya Pradesh). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 524606.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹5.07 Cr. It is led by directors including Sanjay Sethi (Managing Director) and Shailendra Pathak (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 29 Neer Nagar Mayank Water Park Road Bicholi, Indore, Madhya Pradesh, India – 452016.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹19.31 Cr, a decline of 8.7% compared to the previous year. For the same year it recorded a net profit of ₹44 Lakh (net margin 2.3%) and EBITDA of ₹2.43 Cr (EBITDA margin 12.6%). The net worth stands at ₹9.88 Cr (up 4.2% YoY). Total assets are valued at ₹12.84 Cr (down 8.4% YoY).
The company has about 22 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Beryl Drugs. As per MCA filings, the company has open charges of ₹2.85 Cr and satisfied charges of ₹9.99 Cr on record. Court records list 7 cases involving the company, including 2 filed by the company and 5 filed against it. The company has 259 deals on record (259 market trades); the latest was in April 2026. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Astamed Healthcare ( India ) Private Limited with revenue of ₹22.66 Cr. The company has 8 MSME Form 1 returns on record between 2020 and 2023, listing 264 overdue payments to 10 micro and small suppliers.
Beryl Drugs Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MP-17-0000764). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website beryldrugs.com.
Company details
CIN L02423MP1993PLC007840
Registration Number 007840
Incorporation Date 24 August 1993
ROC Gwalior
Listing Status Listed - Listed on BSE (524606)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MP-17-0000764
CIN history
Beryl Drugs has one previous CIN (Corporate Identification Number): U02423MP1993PLC007840. The current CIN is L02423MP1993PLC007840, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L02423MP1993PLC007840 | Current |
| U02423MP1993PLC007840 | Previous |
Key People
Sanjay Sethi Managing Director Shailendra Pathak Whole-Time Director Sudhir Sethi Director Recognitions & Rankings of Beryl Drugs
Contact details
Beryl Drugs Limited's registered office is in Indore, Madhya Pradesh. Its website is beryldrugs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address29 Neer Nagar Mayank Water Park Road Bicholi, Indore, Madhya Pradesh, India – 452016
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Beryl Drugs Limited, buy the company report.
Comprehensive company report
Beryl Drugs Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Beryl Drugs operates one associated brand: Beryl Drugs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical and allied healthcare products are manufactured for various supplies. | beryldrugs.com |
Business activity
The main business activity of Beryl Drugs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Beryl Drugs Limited, buy the company report.
Financials of Beryl Drugs Limited
FY 2025-26 filings availableBeryl Drugs Limited reported revenue of ₹19.31 Cr (down 8.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹19.31 Cr
-8.7% YoY
EBITDA
₹2.43 Cr
+94.4% YoY
Profit After Tax
₹0.44 Cr
-24.1% YoY
Net Worth
₹9.88 Cr
+4.2% YoY
Total Assets
₹12.84 Cr
-8.4% YoY
Total Debt
₹2.44 Cr
-40.8% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 19.31 | 21.15 | 26.73 | 26.89 | 14.60 | 14.09 | 12.82 |
| Revenue growth | -8.7% | -20.9% | -0.6% | +84.2% | +3.6% | +9.9% | - |
| EBITDA | 2.43 | 1.25 | 2.29 | 2.01 | 0.43 | 1.44 | 0.91 |
| EBITDA margin | +12.6% | +5.9% | +8.6% | +7.5% | +3.0% | +10.2% | +7.1% |
| Profit before tax | 0.60 | 0.87 | 1.02 | 1.00 | (0.96) | 0.34 | 0.16 |
| Net profit | 0.44 | 0.58 | 0.77 | 0.78 | (0.67) | (0.11) | 0.05 |
| Net profit margin | +2.3% | +2.7% | +2.9% | +2.9% | -4.6% | -0.8% | +0.4% |
| EPS (₹) | 0.84 | 1.14 | 1.51 | 1.50 | (1.29) | 0.47 | 0.09 |
| Balance sheet | |||||||
| Total assets | 12.84 | 14.02 | 14.42 | 13.01 | 12.95 | 13.37 | 13.13 |
| Net worth | 9.88 | 9.48 | 8.92 | 8.06 | 7.29 | 7.93 | 7.62 |
| Total debt | 2.44 | 4.12 | 5.09 | 4.54 | 5.29 | 5.12 | 5.23 |
| Cash & bank | 0.27 | 0.81 | 0.12 | 0.57 | 0.27 | 0.45 | 0.40 |
| Net working capital | 4.74 | 7.08 | 7.04 | 5.80 | 5.76 | 5.07 | 3.81 |
| Cash flow | |||||||
| Cash from operations | 3.65 | 3.29 | 0.82 | 2.48 | (0.29) | 0.34 | 0.18 |
| Cash from investing | (2.16) | (1.05) | (1.08) | (1.30) | 0.54 | 0.26 | (1.55) |
| Cash from financing | (2.03) | (1.56) | 0.10 | (1.17) | (0.43) | (0.54) | 1.67 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.57 | 5.47 | 3.85 | 5.16 | 4.83 | 5.22 | 5.40 | 5.64 |
| Revenue growth (YoY) | +56.7% | +4.8% | -28.7% | -8.5% | -23.2% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 6.92 | 4.13 | 4.05 | 4.42 | 4.28 | 4.72 | 4.81 | 5.08 |
| EBITDA | 0.65 | 1.34 | (0.20) | 0.74 | 0.55 | 0.50 | 0.59 | 0.56 |
| EBITDA margin | +8.9% | +26.1% | -5.3% | +14.5% | +11.5% | +12.6% | +11.1% | +10.0% |
| Depreciation | 0.32 | 0.40 | 0.32 | 0.39 | 0.38 | 0.32 | 0.31 | 0.33 |
| Interest | 0.06 | 0.07 | 0.09 | 0.08 | 0.10 | 0.08 | 0.12 | 0.12 |
| Profit before tax | 0.27 | 0.87 | (0.61) | 0.27 | 0.07 | 0.10 | 0.16 | 0.11 |
| Tax | 0.05 | 0.30 | (0.44) | 0.25 | 0.05 | (0.05) | 0.10 | 0.10 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.57 | 5.47 | 3.85 | 5.16 | 4.83 | 5.22 | 5.40 | 5.64 |
| Revenue growth (YoY) | +56.7% | +4.8% | -28.7% | -8.5% | -23.2% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 6.92 | 4.13 | 4.05 | 4.42 | 4.28 | 4.72 | 4.81 | 5.08 |
| EBITDA | 0.65 | 1.34 | (0.20) | 0.74 | 0.55 | 0.50 | 0.59 | 0.56 |
| EBITDA margin | +8.9% | +26.1% | -5.3% | +14.5% | +11.5% | +12.6% | +11.1% | +10.0% |
| Depreciation | 0.32 | 0.40 | 0.32 | 0.39 | 0.38 | 0.32 | 0.31 | 0.33 |
| Interest | 0.06 | 0.07 | 0.09 | 0.08 | 0.10 | 0.08 | 0.12 | 0.12 |
| Profit before tax | 0.27 | 0.87 | (0.61) | 0.27 | 0.07 | 0.10 | 0.16 | 0.11 |
| Tax | 0.05 | 0.30 | (0.44) | 0.25 | 0.05 | (0.05) | 0.10 | 0.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 19.31 | 21.15 | 26.73 | 26.89 | 14.60 | 14.09 | 12.82 |
| Revenue growth | -8.7% | -20.9% | -0.6% | +84.2% | +3.6% | +9.9% | - |
| Other income | 0.00 | 1.41 | 0.40 | 0.27 | 0.16 | 0.64 | 0.23 |
| Total expenses | 16.88 | 19.90 | 24.44 | 24.88 | 14.17 | 12.65 | 11.91 |
| Employee cost | 0.00 | 2.21 | 1.93 | 1.70 | 1.31 | 1.18 | 0.97 |
| EBITDA | 2.43 | 1.25 | 2.29 | 2.01 | 0.43 | 1.44 | 0.91 |
| EBITDA margin | +12.6% | +5.9% | +8.6% | +7.5% | +3.0% | +10.2% | +7.1% |
| Depreciation | 1.49 | 1.25 | 1.20 | 0.81 | 1.09 | 1.27 | 0.66 |
| Interest | 0.34 | 0.54 | 0.47 | 0.47 | 0.46 | 0.47 | 0.32 |
| Profit before tax | 0.60 | 0.87 | 1.02 | 1.00 | (0.96) | 0.34 | 0.16 |
| Tax | 0.16 | 0.29 | 0.24 | 0.22 | (0.29) | 0.11 | 0.11 |
| Net profit | 0.44 | 0.58 | 0.77 | 0.78 | (0.67) | (0.11) | 0.05 |
| Net profit margin | +2.3% | +2.7% | +2.9% | +2.9% | -4.6% | -0.8% | +0.4% |
| EPS (₹) | 0.84 | 1.14 | 1.51 | 1.50 | (1.29) | 0.47 | 0.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves & surplus | 4.79 | 4.39 | 3.83 | 2.97 | 2.20 | 2.84 | 2.53 |
| Shareholders' funds (net worth) | 9.88 | 9.48 | 8.92 | 8.06 | 7.29 | 7.93 | 7.62 |
| Secured loans | 2.39 | 4.07 | 5.09 | 4.54 | 1.92 | 2.77 | 2.84 |
| Unsecured loans | 0.05 | 0.05 | 0.00 | 0.00 | 3.37 | 2.35 | 2.39 |
| Total debt | 2.44 | 4.12 | 5.09 | 4.54 | 5.29 | 5.12 | 5.23 |
| Total liabilities | 12.84 | 14.02 | 14.42 | 13.01 | 12.95 | 13.37 | 13.13 |
| Assets | |||||||
| Gross block | 15.45 | 13.17 | 12.06 | 10.86 | 10.06 | 10.46 | 10.26 |
| Net block | 7.04 | 6.24 | 6.16 | 6.03 | 6.04 | 7.53 | 8.60 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.15 | 0.16 | 0.12 | 0.56 |
| Inventories | 3.13 | 1.90 | 1.26 | 1.05 | 2.98 | 2.27 | 1.16 |
| Sundry debtors | 2.09 | 5.46 | 7.58 | 6.90 | 4.45 | 4.54 | 3.45 |
| Cash & bank balances | 0.27 | 0.81 | 0.12 | 0.57 | 0.27 | 0.45 | 0.40 |
| Loans & advances | 1.34 | 0.87 | 1.15 | 1.79 | 2.93 | 2.89 | 2.51 |
| Total current assets | 6.83 | 9.04 | 10.11 | 10.31 | 10.63 | 10.15 | 7.52 |
| Total current liabilities | 2.09 | 1.96 | 3.07 | 4.51 | 4.87 | 5.08 | 3.71 |
| Net working capital | 4.74 | 7.08 | 7.04 | 5.80 | 5.76 | 5.07 | 3.81 |
| Total assets | 12.84 | 14.02 | 14.42 | 13.01 | 12.95 | 13.37 | 13.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.81 | 0.12 | 0.28 | 0.27 | 0.45 | 0.40 | 0.10 |
| Net cash from operating activities | 3.65 | 3.29 | 0.82 | 2.48 | (0.29) | 0.34 | 0.18 |
| Net cash from investing activities | (2.16) | (1.05) | (1.08) | (1.30) | 0.54 | 0.26 | (1.55) |
| Net cash from financing activities | (2.03) | (1.56) | 0.10 | (1.17) | (0.43) | (0.54) | 1.67 |
| Net change in cash | (0.54) | 0.69 | (0.16) | 0.01 | (0.18) | 0.06 | 0.30 |
| Closing cash | 0.27 | 0.81 | 0.12 | 0.57 | 0.27 | 0.45 | 0.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -8.7% | -20.9% | -0.6% | +84.2% | +3.6% | +9.9% | - |
| EBITDA growth | +94.4% | -45.4% | +13.9% | +367.4% | -70.1% | +58.2% | - |
| PBT growth | -31.0% | -14.7% | +2.0% | +9998.0% | - | +112.5% | -79.5% |
| Net income growth | -24.1% | -24.7% | -1.3% | +216.4% | -509.1% | -320.0% | - |
| Revenue CAGR (3Y) | -10.5% | +13.2% | +23.8% | +28.0% | +4.1% | -2.5% | +4.9% |
| EBITDA CAGR (3Y) | +6.5% | +42.7% | +16.7% | +30.2% | -24.8% | +11.8% | - |
| Profitability & leverage | |||||||
| Net income margin | +2.3% | +2.7% | +2.9% | +2.9% | -4.6% | +1.6% | +0.4% |
| Return on capital employed | - | +9.9% | +10.8% | +11.3% | -3.7% | +2.8% | +4.0% |
| Return on net worth | - | +6.3% | +9.1% | +10.0% | -8.7% | -1.3% | +0.7% |
| Debt / equity | - | 0.50 | 0.57 | 0.64 | 0.68 | 0.67 | 0.56 |
| Long-term debt / equity | - | 0.22 | 0.30 | 0.29 | 0.24 | 0.28 | 0.24 |
| Interest cover | 36.17 | - | 43.12 | 39.17 | -69.70 | 276.47 | 128.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.67 | 2.33 | 2.57 | 1.42 | 1.36 | 1.94 |
| Inventory turnover | - | 13.39 | 23.14 | 13.34 | 5.56 | 8.22 | 13.35 |
| Debtors turnover | - | 3.24 | 3.69 | 4.74 | 3.25 | 3.53 | 3.72 |
| EPS (₹) | 0.84 | 1.14 | 1.51 | 1.50 | (1.29) | 0.47 | 0.09 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 18.66 | 17.52 | 15.84 | 14.32 | 15.57 | 14.97 |
To see the full year-wise statements and ratios of Beryl Drugs Limited, buy the company report.
Board of directors and KMP of Beryl Drugs Limited
Beryl Drugs Limited currently reports 6 directors and 1 key managerial person. 10 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sudhir Sethi | Director | 12 Dec 2000 | 25 Years 10 Months | Current |
| Abhinav Naik Also directs: Beryl Securities Limited | Director | 30 May 2019 | 7 Years 5 Months | Current |
| Shreya Saraf | Director | 30 May 2019 | 7 Years 5 Months | Current |
| Neha Sarda Also directs: Beryl Securities Limited, Recharge Trendd Setter Limited | Director | 03 Jan 2026 | 0 Years 10 Months | Current |
| Kamlesh Gupta | Company Secretary | 03 Jan 2026 | 0 Years 10 Months | Current |
| Sanjay Sethi | Managing Director | 12 Dec 2000 | 25 Years 10 Months | Current |
Showing 6 of 7 current directors and KMP. View all directors and KMP
Peer comparison
Beryl Drugs Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Astamed Healthcare ( India ) Private Limited | ₹22.66 Cr (FY 2025) | -10.0% | Mumbai, Maharashtra, India | |||
| Disto Pharmaceuticals Private Limited | ₹22.63 Cr (FY 2024) | -5.0% | Hyderabad, Telangana, India | |||
| Mapaex Remedies Private Limited | ₹22.57 Cr (FY 2017) | -52.0% | Wadhwan, Gujarat, India | |||
| Athulitha Laboratories Private Limited | ₹22.56 Cr (FY 2024) | 66.0% | Hyderabad, Telangana, India | |||
| Sherrington Pharmaceuticals Private Limited | ₹22.55 Cr (FY 2024) | 3.0% | Hyderabad, Telangana, India | |||
| Ancalima Lifesciences Limited | ₹22.53 Cr (FY 2024) | 4.0% | Sonipat, Haryana, India | |||
| Cito Chem Industries Pvt.Ltd. | ₹22.46 Cr (FY 2025) | -18.0% | Indore, Madhya Pradesh, India | |||
| Beryl Drugs Limitedthis company | ₹19.31 Cr (FY 2026) | ₹44 Lakh | 2.3% | -8.7% | 22 | Indore, Madhya Pradesh, India |
To see the full peer comparison of Beryl Drugs Limited, buy the company report.
Auditor
Beryl Drugs Limited is audited by Subhash Chand Jain Anurag & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Subhash Chand Jain Anurag & Associates | FY 2023 | 004733C |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 27.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 72.50%.
Mar 2026
QUARTER
27.50% Promoters
72.50% Retail & Others
Promoter holding - history
Now 27.50% · Mar 2026High 27.50% · Mar 2026Low 26.40% · Jun 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 27.50% | 26.40% | 26.40% | 26.40% |
| Public | 72.50% | 73.60% | 73.60% | 73.60% |
Charges & borrowings
Open charges
₹2.85 Cr
Satisfied charges
₹9.99 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 18 Mar 1997 | 80050275 | Others | ₹2.85 Cr | Open | |
| 27 Jun 2024 | 100945463 | Others | ₹1.75 Cr | Satisfied | |
| 16 May 2024 | 100930830 | Others | ₹45 Lakh | Satisfied | |
| 20 Mar 2023 | 100693923 | Others | ₹1.15 Cr | Satisfied | |
| 12 Jun 2020 | 100346287 | Others | ₹45 Lakh | Satisfied |
To see the full charge records of Beryl Drugs Limited, buy the company report.
Total charge records: 12 View all charges
Deals & funding
Beryl Drugs Limited has 259 deals on record (259 market trades); the latest was in April 2026.
Total deals
259
Market trades
259
Deals on record (5 of 259)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2024 | Market trade | ₹26.2 Lakh | Buyer: an individual Seller: Hindon Traders and Brokers Private Limited |
| Mar 2024 | Market trade | ₹24.7 Lakh | Buyer: Hindon Traders and Brokers Private Limited Seller: an individual |
| Aug 2016 | Market trade | ₹6.9 Lakh | Seller: Jabeen Tradelink Private Limited |
| Aug 2016 | Market trade | ₹1.99 Cr | Buyer: Ashroj Credit (India) Private Limited , 3 individuals Seller: Ashroj Credit (India) Private Limited , 3 individuals |
| Jul 2016 | Market trade | ₹4.4 Cr | Buyer: Ashroj Credit (India) Private Limited , 3 individuals Seller: Ashroj Credit (India) Private Limited , 3 individuals |
To see the full deal history of Beryl Drugs Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Beryl Drugs Limited has 7 court cases on record: 2 filed by Beryl Drugs, 5 filed against it. All cases are disposed.
Total cases
7
Filed by the company
2
Filed against the company
5
Disposed
7
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 3 | 0 |
| High courts | 2 | 0 | 0 |
| Supreme Court | 2 | 2 | 0 |
Cases on record (5 of 7)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BIDAR, Karnataka | Criminal miscellaneous application | Filed against the company by an individual | Disposed |
| Allahabad High Court | Writ petition | Filed by the company against Union of India Thru. Cabinet Secy. Health and Family Wel.And Ors | Disposed |
| Supreme Court | Court case (0420-Indirect Taxes Matters : Interpretation of exemption notifications under Central Excise Act) | Filed against the company by Union of India Ministry of Customs and Central Excise Through Secretary Through Secretary New Delhi ,New Delhi , Delhi and 1 other | Disposed |
| Supreme Court | Court case (9999-Other) | Filed against the company by Commissioner of Central Excise, Indore | Disposed |
| Allahabad High Court | Writ petition | Filed by the company against State of U.P. Thru Prin.Secy. Medical Health and 5 Ors. | Disposed |
To see the full case history of Beryl Drugs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Beryl Drugs Limited has 8 MSME Form 1 returns on record between 2020 and 2023, listing 264 overdue payments to 10 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 10)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| National Trading Corporation | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Beryl Drugs Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Beryl Drugs Limited has a workforce of 22 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.
Employee count
22
Active EPFO establishments
1
Employee growth
4.76%
GST
Beryl Drugs has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AABCB2664H1Z0 | Madhya Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Beryl Drugs Limited, buy the company report.
Recent activity
Beryl Drugs Limited has 17 board changes on record since 2000: 7 appointments and 10 cessations. The latest: Kamlesh Gupta was appointed as Company Secretary on 03 Jan 2026.
Charges
A charge registered on 20 Mar 2023 via Charge ID 100693923 with Others was fully satisfied on 11 May 2026.
Charges
A charge registered on 27 Jun 2024 via Charge ID 100945463 with Others was fully satisfied on 30 Apr 2026.
Filing
Beryl Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Gwalior.
Appointed
Kamlesh Gupta was appointed as Company Secretary.
Appointed
Neha Sarda was appointed as Director.
Ceased
Neha Sharma ceased to be Company Secretary.
Appointed
Shailendra Pathak was appointed as Whole-Time Director.
AGM
Beryl Drugs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge registered on 16 May 2024 via Charge ID 100930830 with Others was fully satisfied on 15 Apr 2025.
Charges
A charge with Others of Rs. 2.85 Cr registered on 18 Mar 1997 with Charge ID 80050275 was modified on 15 Mar 2025.
Charges
A charge with Others amounted to Rs. 1.75 Cr with Charge ID 100945463 was registered on 27 Jun 2024.
Charges
A charge with Others amounted to Rs. 0.45 Cr with Charge ID 100930830 was registered on 16 May 2024.
35 earlier events are in the company report.
Frequently asked questions
Beryl Drugs is an active public limited company based in Indore, Madhya Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 August 1993 (33+ years old) and is registered under CIN L02423MP1993PLC007840. Listed on BSE: 524606.
Beryl Drugs reported revenue of ₹19.31 Cr for FY 2025-26 (down 8.7% YoY) based on standalone financials.
Beryl Drugs has 7 current directors and KMP:
- Sanjay Sethi - Managing Director
- Shailendra Pathak - Whole-Time Director
- Sudhir Sethi - Director
- Abhinav Naik - Director
- Shreya Saraf - Director
- Neha Sarda - Director
- Kamlesh Gupta - Company Secretary
The latest financial statements of Beryl Drugs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Beryl Drugs is 23AABCB2664H1Z0, registered in Madhya Pradesh. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Beryl Drugs is L02423MP1993PLC007840. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Beryl Drugs is a listed company as per MCA records. Its shares are listed on BSE (code: 524606).
Beryl Drugs has 7 court cases on record: 2 filed by the company and 5 filed against it. Most are in the district courts.
Beryl Drugs was incorporated on 24 August 1993, making it 33+ years old. It is registered with the Registrar of Companies, Gwalior.
Beryl Drugs has 259 deals on record (259 market trades); the latest was in April 2026.
The peers of Beryl Drugs by revenue are Astamed Healthcare ( India ) Private Limited, Disto Pharmaceuticals Private Limited, Mapaex Remedies Private Limited, Athulitha Laboratories Private Limited, Sherrington Pharmaceuticals Private Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Kamlesh Gupta was appointed as Company Secretary on 03 Jan 2026. Neha Sarda was appointed as Director on 03 Jan 2026. Neha Sharma ceased to be Company Secretary on 03 Jan 2026. Beryl Drugs has 17 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages